Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-07-25
2010-12-14
Chernyshev, Olga N (Department: 1649)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007900, C435S007100, C436S501000
Reexamination Certificate
active
07851172
ABSTRACT:
A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein.
REFERENCES:
patent: 4728605 (1988-03-01), Fudenberg et al.
patent: 5874312 (1999-02-01), Sredni et al.
patent: 6027896 (2000-02-01), Roses
patent: 6114133 (2000-09-01), Seubert
patent: 6130048 (2000-10-01), Nixon
patent: 6210895 (2001-04-01), Schipper
patent: 6358681 (2002-03-01), Ginsberg
patent: 6451547 (2002-09-01), Jackowski
patent: 6458549 (2002-10-01), Maesaka
patent: 6461831 (2002-10-01), Small
patent: 6465195 (2002-10-01), Holtzman
patent: 6475161 (2002-11-01), Teicher
patent: 6495335 (2002-12-01), Chojkier
patent: 2001/0021508 (2001-09-01), Maesaka
patent: 2004/0072261 (2004-04-01), Kostanjevecki
patent: 2005/0221348 (2005-10-01), Ray et al.
patent: 2005/0244890 (2005-11-01), Davies et al.
patent: 2006108051 (2004-08-01), None
patent: 2004001421 (2006-10-01), None
Stark et al., 2001, J. Chromatography, 754, pp. 357-367.
Yuan et al., 2005, Proteomics, 5, pp. 541-550.
Castano et al., 2006, Neurolog. Research, 28, pp. 155-163.
Zhang et al., 2005, J. Alzheimer's disease, 8, pp. 377-386.
Biroccio et al., 2006, Proteomics, 6, pp. 2305-2313.
Johanson et al., 2005, Blood-cerebrospinal fluid barrier, Taylor&Frances, 2005, pp. 311-343.
Blennow, et al. Dementia. 6(6):306-11 (1995).
Burbach, et al. 2004, J. Neurosci. 24 (10), 2421-2430.
Carrette, O. et al, Proteomics, 3:1486-1494 (2003).
Davidson et al., Neuroreport, 13:611-615 (2002).
Elovaara Acta, Neurol Scand. 69(5):302-5(1994).
Fahnestock, et al., 2002, J. Neural. Transm. Suppl. 2002(62):241-52.
Harigaya et al. Intern Med. 34(6):481-4 (1995).
Harrington, et al., Appl. Theoret Electrophor 3:229-34 (1993).
Hiraoka, et al., J. Chormatogr A 802:143-48 (1998).
Hoekman, et al., Neth. J. Med. 28:551-557 (1985).
Huhmer, et al., Disease Markers 22:3-26 (2006).
Iqbal , et al., J. Neural Transm Suppl. 53:169-80 (1998).
Kawashima, Mod. Pathol. 14:197-201 (2001).
Kudo, et al., Brain Res. 639 (1): 1-7 (1994).
Li, et al., (2002, Neuroscience 113 (3): 607-15).
Mase. Neurosci Res 47:455-459 (2003).
Matsubara, et al., Ann. Neurol 28(4):561-7(1990).
McKhann, et al., Neurology 34:939-48 (1984).
Melegos, et al., Prostaglandins 54:463-474 (1997).
Merched, et al., FEBS Lett. 425(2):225-8 (1998).
Peterson, et al., Arch Neurol 56:303-308 (1999).
Price and Morris, Ann Neurol 45:358-68 (1999).
Sanna, et al., (2003, J. Clin. invest. 111(2):241-50).
Serot, et al., J Neurol Neurosurg Psychiatry. 63(4)-506-8 (1997).
Skoog, et al., Neurology. 50:966-71 (1998).
Tzuzuki, et al., Neurosci Lett, 10:171-174 (2000).
Wang, et al., Acta Neuropathol (Berl). 82(1):6-12 (1991).
Martin, et al., J. Eukaryot., Microbiol., 54(1), 2007 pp. 25-28.
Sun, et al., 2007 American Society for Mass Spectrometry, 1044-0305.
Wiliams, et al., Appl. Microbiol Biotechnol (2007) 74:422-432.
McCollum, et al., Experimental Neurology 2002 (2006) 506-513.
Williams, et al., Electrophoresis 2006, 27, 2984-2995.
Liu, et al, Chem. Res. Toxicol. 2006, 19, 710-718.
Wang, et al., Molecular and Cellular Biology, Dec. 2005, p. 10745-10754.
Kimball, et al., Neurobiology of Aging 27 (2006) 1239-1249.
Poon, et al., Free Radical Biology & Medicine 39 (2005) 453-462.
Kimball, et al., Brain Research 1044 (2005) 206-215.
Kimball, et al., Neuroscience 132 (2005) 313-324.
Pocernich, et al., Molecular Brain Research 133 (2005) 307-316.
Pocernich, et al., Molecular Brain Research 133 (2005) 299-306.
Kimball, et al., Journal of Neuroscience Research 79:707-713 (2005).
Poon, et al., Neurochemistry international 46 (2005) 159-168.
Poon, et al., Neuroscience 126 (2004) 915-926.
Castegna, et al., Journal of Neurochemistry, 2004, 88, 1540-1546.
Wenner, et al., Journal of Proteome Research, 2004: 3, 97-103.
Wenner, et al., Journal American Society for Mass Spectrometry, 2004, 15, 150-157.
Wiliams, et al., Neurobiology of Aging 27 (2006) 1094-1099.
Xiong, et al., Antioxidants & Redox Signaling vol. 9, No. 4, 2007.
Lovell, et al., Journal Neuropathol. Exp Neurol, vol. 64, No. 8, Aug. 2005, pp. 675-680.
Lovell, et al., Journal Neuropathol. Exp Neurol, vol. 65, No. 5, May 2006, pp. 489-498.
Wenner, et al., Journal of Proteome Research, 2004, 3, 97-103.
Mark, et al., Journal of Neurochemistry, vol. 68, No. 1, 1997.
Xie, et al., Brain Research 743 (1996) 271-277.
Sullivan, et al., The Journal of Comparitive Neurology 474:524-534 (2004).
Markesberry, et al., Antioxidants & Redox Signaling, vol. 8, No. 11 & 12, 2006.
Smith, et al., NeuroToxicology 27 (2006) 1-5.
Liu, et al., Chem. Res. Toxicol. 2006, 19, 710-718.
Wang, et al., Journal of Neurochemistry. 2006, 96, 825-832.
Markesbery, et al., Annals of Neurology, vol. 58, No. 5, Nov. 2005.
Liu, et al., Anal. Chem. 2005, 77, 5982-5989.
Smith, et al., NeuroToxicoloqy 27 (2006) 1-5.
Wang, et al., Journal of Neurochemistry, 2005, 93, 953-962.
Williams, et al., Anal. Chem. 2005, 77, 3383-3389.
Lovell, et al., Neurochemical Research, vol, 30, No. 1, Jan. 2005, pp. 113-122.
Lovell, et al., Neurobiology of Aging 22 (2001) 187-194.
Lovell, et al., Arch Neurol/vol. 58, Mar. 2001.
Lovell, et al., Free Radical Biology & Medicine, vol. 29, No. 8, pp. 714-720.
Lovell, et al., Brain Research 855 (2000) 116-123.
Gabbita, et al., Journal of Neurochemistry, 73, 1660-1666 (1999).
Prasad, et al., Neurochemical Research, vol. 23, No. 1, 1998, pp. 81-88.
Lovell, et al., Neurobiology of Aging, vol. 18, No. 5, pp. 457-461 1997.
Shao, et al., Free Radical Biology & Medicine 41 (2006) 77-85.
Smith, et al., Neuroscience 140 (2006) 879-888.
Lovell, et al., Neurobiology of Aging 27 (2006) 909 -917.
Lovell, et al., Brain Research 823 (1999) 88-95.
Rulon, et al., Biological Trace Element Research, vol. 75, 2000.
Lovell, et al., Brain Research 983 (2003) 84-96.
Lovell, et al., Free Radical Biology & Medicine, vol. 28, No, 3, pp. 418-427, 2000.
Lovell, et al., Neurobiology of Aging 23 (2002) 179-186.
Lovell, et al., Journal of Alzheimer's Disease 5 (2003) 229-239.
Gabbita, et al., Journal of Neurochemistry, vol. 71, No. 5, 1998.
Xie, et al., Free Radical Biology & Medicine, vol. 25, No. 8. pp. 979-988, 1998.
Lovell, et al., Journal of Neurochemistry, vol, 72, No. 2, 1999.
Mattson, et al., Brain Research, 602 (1993) 21-31.
Lovell, et al., Journal of the Neurological Sciences 158 (1998) 47-52.
Xie, et al., Free Radical Biology & Medicine, vol. 31, No. 1, pp. 73-81, 2001.
Lovell, et al., 1594, Neurology, 45, Aug. 1995.
Hiraoka, et al., 2001, Electrophoresis, 22, pp. 3433-3437.
Stark M. et al,: Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins; J. of chromatography B: Biomedical applications; 2001; vol. 754, No. 2, 2001, pp. 357-367.
Supplemental European Search Report; Sep. 14, 2009.
Lovell Mark A.
Lynn Bert C.
Chernyshev Olga N
University of Kentucky Research Foundation
Viksnins Harris & Padys PLLP
LandOfFree
Biomarkers of mild cognitive impairment and alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biomarkers of mild cognitive impairment and alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers of mild cognitive impairment and alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185903